SAMiRNA™
SAMiRNA는 세계 최초로 개발된 siRNA 나노입자 기반 prodrug 입니다. 생 분해성의 자가조립미셸 siRNA 나노입자 (SAMiRNA, Self-Assembled Micelle siRNA Nanoparticle)로 뛰어난 전달효과 및 siRNA 약효를 나타냅니다. 암과 다양한 질병모델 치료제로 적용 가능합니다.
특허 출원된 독창적인 구조의 자가조립 siRNA 나노 입자 (그림 1)는 외부의 PEG 층에 의해 내부 siRNA 가 보호되는 형태를 가집니다. 최적화된 나노 스케일의 사이즈로 EPR (Enhanced Permeability and Retention)효과에 의해 종양조직이나 SAMiRNA 표면에 부착된 타겟팅 물질에 의해 목표 질병 장기로 선택적으로 전달됩니다.
| The world's first siRNA prodrug technology |
높은 혈장 안정성을 가지며, 목표 세포에 전달되어 대사되었을 때만 siRNA가 활성화되어 knockdown 효능을 나타냄 |
| Powerful siRNA delivery platform technology |
다양한 타겟팅 물질의 부착을 통해 SAMiRNA 나노입자를 다양한 목표 장기로 표적화 가능. |
| in vivo efficacy validated in animal disease models via low dose I.V. injection |
암 관련 유전자의 in vivo 기능에 대한 전임상 동물 연구에 적합 |
| Competitive pricing |
신약개발을 위한 타겟 유전자 및 RNAi 치료제 후보유전자의 가장 경제적이고 효과적인 in vivo 검증 |
| Extremely low toxicity and cytokine induction |
Cytokine 유발 및 독성이 매우 낮아 전달체에의한off-targeting 효과가 최소화됨 |
SAMiRNA (Self-Assembled-Micelle-interfering-RNA)
One of the major hurdles for the development of RNA interference (RNAi)-based therapeutics is siRNA delivery. SAMiRNA (Self-Assembled-Micelle-interfering-RNA) is a novel class of RNAi molecule developed by Bioneer. The therapeutic potential of SAMiRNA is highlighted by virtue of its negligible toxicity and superb in vivo serum stability as well as its target gene silencing efficacy. These data indicate SAMiRNA's exceptional therapeutic potential as an RNAi platform for a variety of diseases.
Development of SAMiRNA system combines Bioneer's extensive nucleic acid chemistry and pre-clinical research with our nucleic acid manufacturing and development expertise, which has been providing top-quality DNA oligos and siRNAs worldwide for close to 20 years..
Delivery challenges overcome by SAMiRNA technology
| Challenges in siRNA delivery |
SAMiRNA NP system |
| Rapid clearance and degradation in serum |
Improved serum stability |
| Toxicity of delivery systems |
No detectable liver toxicity or innate immune response |
| Tissue specificity |
Tumor/tissue targeting capabilities |
| Silencing potency |
Long lasting in vivo silencing efficiency |
바이오니아 SAMiRNA™를 이용한 siRNA 신약개발 Program
Vertically integrated processes within Bioneer's siRNA Drug Development Programprovide a total solution for siRNA therapeutics discovery and development, from siRNA design/synthesis and preclinical tests to IND filing. With its world's-best RNAi core technologies and manufacturing infrastructure, Bioneer is the ideal partner for pharmaceutical and biotechnology companies currently working on the development of RNAi therapeutics, or seeking to enter the RNAi field. The company's research and technical support teams ensure top-quality products and services to meet your unique needs.
Our siRNA Drug Development Program includes:
- Design and synthesis of siRNAs (custom siRNA synthesis using patented design algorithm, which has been used for genome-wide siRNA libraries for human, mouse and rat)
- in vitro screening and validation of siRNAs including MIQE qPCR analysis
- Preclinical test using SAMiRNA including in vivo siRNA delivery and biodistribution/efficacy test using murine and non-human primate models
- Large scale manufacturing of SAMiRNA (in house raw material manufacturing facilities, fully automated siRNA/SAMiRNA synthesis pipeline)
- Drug candidates efficacy/toxicity tests in nonhuman primate (through collaboration with Korea Institute of Toxicology)
- And much more…
Please see below our siRNA core technologies and siRNA Drug Development Program Roadmap.
Bioneer's siRNA Drug Development Program will provide a rapid on-line quotation (siRNA@bioneer.com). Please let us know the details of your project, so that we can provide you with an accurate quotation and timeline estimate.
Please click each step for more information